Compare VNRX & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | TRIB |
|---|---|---|
| Founded | N/A | 1992 |
| Country | United States | Ireland |
| Employees | 75 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.4M |
| IPO Year | 2012 | 1996 |
| Metric | VNRX | TRIB |
|---|---|---|
| Price | $0.25 | $6.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 7.9K |
| Earning Date | 05-12-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $355.66 | $13.51 |
| Revenue Next Year | $849.08 | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.28 |
| 52 Week High | $3.26 | $14.17 |
| Indicator | VNRX | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 29.22 | 31.50 |
| Support Level | $0.22 | $0.55 |
| Resistance Level | $0.27 | $14.03 |
| Average True Range (ATR) | 0.02 | 0.45 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 24.28 | 0.00 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.